Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Long-Term Debt Repayments (2023)

Historic Long-Term Debt Repayments for Contineum Therapeutics (CTNM) over the last 1 years, with Q2 2023 value amounting to $3.1 million.

  • Contineum Therapeutics' Long-Term Debt Repayments changed N/A to $3.1 million in Q2 2023 from the same period last year, while for Mar 2024 it was $3.1 million, marking a year-over-year change of. This contributed to the annual value of $3.8 million for FY2023, which is N/A changed from last year.
  • As of Q2 2023, Contineum Therapeutics' Long-Term Debt Repayments stood at $3.1 million.
  • Contineum Therapeutics' 5-year Long-Term Debt Repayments high stood at $3.1 million for Q2 2023, and its period low was $625000.0 during Q1 2023.